Skip to main content

Table 2 Patient disposition

From: Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors

  Everolimus 5 mg/day
(n = 12)
Everolimus 10 mg/day
(n = 12)
Ongoing, n (%) 2 (16.7) 1 (8.3)
Discontinued, n (%) 10 (83.3) 11 (91.7)
   Patient withdrew consent 1 (8.3) 2 (16.7)
   Death 0 2 (16.7)
   Disease progression 9 (75.0) 7 (58.3)